
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midomafetamine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
Details : MDMA (3,4-methylenedioxymethamphetamine) is being evaluated in mid-stage clinical trials for the treatment of PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 20, 2024
Lead Product(s) : Midomafetamine,Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Steven & Alexandra Cohen Foundation
Deal Size : $5.0 million
Deal Type : Funding
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
Details : The grant provides MAPS with vital mission support as it enters the final stages of the drug development process for MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for the treatment of PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Steven & Alexandra Cohen Foundation
Deal Size : $5.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this first Phase 3 trial of any psychedelic-assisted therapy, participants who received MDMA-assisted therapy reported a significant reduction in PTSD symptoms vs those who received placebo with therapy, achieving the prespecified primary endpoint for...
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 03, 2021
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
